These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 23574779)

  • 1. 8q24 amplification is associated with Myc expression and prostate cancer progression and is an independent predictor of recurrence after radical prostatectomy.
    Fromont G; Godet J; Peyret A; Irani J; Celhay O; Rozet F; Cathelineau X; Cussenot O
    Hum Pathol; 2013 Aug; 44(8):1617-23. PubMed ID: 23574779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluorescence in situ hybridization analysis of c-myc amplification in stage TNM prostate cancer in Japanese patients.
    Sato H; Minei S; Hachiya T; Yoshida T; Takimoto Y
    Int J Urol; 2006 Jun; 13(6):761-6. PubMed ID: 16834657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ-confined prostate cancer.
    Tsuchiya N; Slezak JM; Lieber MM; Bergstralh EJ; Jenkins RB
    Genes Chromosomes Cancer; 2002 Aug; 34(4):363-71. PubMed ID: 12112525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization.
    Jenkins RB; Qian J; Lieber MM; Bostwick DG
    Cancer Res; 1997 Feb; 57(3):524-31. PubMed ID: 9012485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A molecularly genetic determination of prognostic factors of the prostate cancer and their relationships to expression of protein p27kip1.
    Dvorácková J; Uvírová M
    Neoplasma; 2007; 54(2):149-54. PubMed ID: 17319789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.
    Qian J; Hirasawa K; Bostwick DG; Bergstralh EJ; Slezak JM; Anderl KL; Borell TJ; Lieber MM; Jenkins RB
    Mod Pathol; 2002 Jan; 15(1):35-44. PubMed ID: 11796839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy.
    Grupp K; Höhne TS; Prien K; Hube-Magg C; Tsourlakis MC; Sirma H; Pham T; Heinzer H; Graefen M; Michl U; Simon R; Wilczak W; Izbicki J; Sauter G; Minner S; Schlomm T; Steurer S
    Exp Mol Pathol; 2013 Oct; 95(2):227-34. PubMed ID: 23948277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic profile identification in clinically localized prostate carcinoma.
    Gallucci M; Merola R; Leonardo C; De Carli P; Farsetti A; Sentinelli S; Sperduti I; Mottolese M; Carlini P; Vico E; Simone G; Cianciulli A
    Urol Oncol; 2009; 27(5):502-8. PubMed ID: 18534873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
    Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
    Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue expression of IL16 in prostate cancer and its association with recurrence after radical prostatectomy.
    Compérat E; Rouprêt M; Drouin SJ; Camparo P; Bitker MO; Houlgatte A; Cancel-Tassin G; Cussenot O
    Prostate; 2010 Nov; 70(15):1622-7. PubMed ID: 20687232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
    Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
    Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The rs6983267 SNP is associated with MYC transcription efficiency, which promotes progression and worsens prognosis of colorectal cancer.
    Takatsuno Y; Mimori K; Yamamoto K; Sato T; Niida A; Inoue H; Imoto S; Kawano S; Yamaguchi R; Toh H; Iinuma H; Ishimaru S; Ishii H; Suzuki S; Tokudome S; Watanabe M; Tanaka J; Kudo SE; Mochizuki H; Kusunoki M; Yamada K; Shimada Y; Moriya Y; Miyano S; Sugihara K; Mori M
    Ann Surg Oncol; 2013 Apr; 20(4):1395-402. PubMed ID: 22976378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer.
    Montironi R; Mazzucchelli R; Barbisan F; Stramazzotti D; Santinelli A; Scarpelli M; Lòpez Beltran A
    Hum Pathol; 2006 Sep; 37(9):1137-44. PubMed ID: 16938518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aneusomy of chromosomes 7, 8, and 17 and amplification of HER-2/neu and epidermal growth factor receptor in Gleason score 7 prostate carcinoma: a differential fluorescent in situ hybridization study of Gleason pattern 3 and 4 using tissue microarray.
    Skacel M; Ormsby AH; Pettay JD; Tsiftsakis EK; Liou LS; Klein EA; Levin HS; Zippe CD; Tubbs RR
    Hum Pathol; 2001 Dec; 32(12):1392-7. PubMed ID: 11774175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapy.
    Locke JA; Zafarana G; Ishkanian AS; Milosevic M; Thoms J; Have CL; Malloff CA; Lam WL; Squire JA; Pintilie M; Sykes J; Ramnarine VR; Meng A; Ahmed O; Jurisica I; van der Kwast T; Bristow RG
    Clin Cancer Res; 2012 Jan; 18(1):308-16. PubMed ID: 22048240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of chromosomal anomalies and c-myc gene amplification in the cribriform pattern of prostatic intraepithelial neoplasia and carcinoma by fluorescence in situ hybridization.
    Qian J; Jenkins RB; Bostwick DG
    Mod Pathol; 1997 Nov; 10(11):1113-9. PubMed ID: 9388062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.
    Bañez LL; Sun L; van Leenders GJ; Wheeler TM; Bangma CH; Freedland SJ; Ittmann MM; Lark AL; Madden JF; Hartman A; Weiss G; Castaños-Vélez E
    J Urol; 2010 Jul; 184(1):149-56. PubMed ID: 20478579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy.
    Li T; Gui Y; Yuan T; Liao G; Bian C; Jiang Q; Huang S; Liu B; Wu D
    BJU Int; 2012 Dec; 110(11 Pt C):E1125-30. PubMed ID: 22672360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative copy number gain of MYC in diagnostic needle biopsies is an independent prognostic factor for prostate cancer patients.
    Ribeiro FR; Henrique R; Martins AT; Jerónimo C; Teixeira MR
    Eur Urol; 2007 Jul; 52(1):116-25. PubMed ID: 17070983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer.
    Minner S; Jessen B; Stiedenroth L; Burandt E; Köllermann J; Mirlacher M; Erbersdobler A; Eichelberg C; Fisch M; Brümmendorf TH; Bokemeyer C; Simon R; Steuber T; Graefen M; Huland H; Sauter G; Schlomm T
    Clin Cancer Res; 2010 Mar; 16(5):1553-60. PubMed ID: 20179235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.